Gene regulation and biophysiological significance of angiotensin type 2 receptor

血管紧张素2型受体的基因调控及其生物生理意义

基本信息

  • 批准号:
    09470175
  • 负责人:
  • 金额:
    $ 8.45万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1998
  • 项目状态:
    已结题

项目摘要

The receptors for angiotensin (Ang) II are classified into Iwo subtypes (AT1-R and AT2-R) by the discovery of non-peptidic ligands and AT1-R mediates most of the cardiovascular actions of Ang II.AT2-R is expressed at very high levels in the developing fetus, whereas in the adult its expression in the cardiovascular system is very low. The expression of AP2-R can be modulated by pathological states associated with tissue remodeling or inflammation. In failing hearts or neointima formation after vascular injury, AT2-R is re-expressed in cells proliferating in interstitial regions or neointima and exerts an inhibitory effect on Ang II-induced mitogen signals or synthesis of extracellular matrix proteins, resulting in attenuation of the tissue remodeling. An extreme way of cell growth inhibition directs cells into programmed cell death, and its process initiated by withdrawal of growth factors is also enhanced by AT2-R.Cardiac myocyte- or vascular smooth muscle-specific overexpression mice of AT2-R display an inhibitory effect on Ang II-induced chronotropic or pressor actions, suggesting the role of AT2-R on the activity of cardiac pacemaker cells or maintenance of vascular resistance. AT2-R also activates the kinin/nitric oxide/cGMP system in the cardiovascular and renal system, resulting in the AT2-R-mediated cardioprotection, vasodilation and pressure nairiuresis. These effects transmitted by AT2-R are mainly exerted by stimulation of protein tyrosine or serine/threonine phosphatases in Gi-protein dependent manner. The expression level of AT2-R is much higher in human hearts than in those of rodents, and the AT2-R-mediated actions are likely enhanced, especially by clinical application of AT1-R antagonists.
血管紧张素Ⅱ(Angiotensin,Ang)Ⅱ受体通过非肽配体的发现分为伊沃亚型(AT 1-R和AT 2-R),AT 1-R介导Ang Ⅱ的大部分心血管作用,AT 2-R在发育中的胎儿中表达水平很高,而在成人心血管系统中表达水平很低。AP 2-R的表达可以通过与组织重塑或炎症相关的病理状态来调节。在心力衰竭或血管损伤后新生内膜形成中,AT 2-R在间质区或新生内膜中增殖的细胞中重新表达,并对Ang II诱导的有丝分裂原信号或细胞外基质蛋白的合成产生抑制作用,导致组织重塑减弱。细胞生长抑制的一种极端的方式直接细胞进入程序性细胞死亡,其过程中启动的生长因子的撤回也增强了AT 2-R。心肌细胞或血管平滑肌特异性过表达小鼠的AT 2-R显示抑制作用,血管紧张素II诱导的变时性或升压作用,这表明心脏起搏细胞的活性或维持血管阻力的作用AT 2-R。AT 2-R还激活心血管和肾脏系统中的激肽/一氧化氮/cGMP系统,导致AT 2-R介导的心脏保护、血管舒张和压力性尿失禁。AT 2-R的这种作用主要是通过刺激蛋白酪氨酸或丝氨酸/苏氨酸磷酸酶来实现的,依赖于Gi蛋白。AT 2-R在人心脏中的表达水平远高于啮齿类动物,AT 2-R介导的作用可能会增强,特别是通过临床应用AT 1-R拮抗剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ohkubo N, et al: "Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell gravth and fibrillar Collagen metlldism" Circulation. 96・10. 3954-3962 (1997)
Ohkubo N 等人:“血管紧张素 2 型受体由衰竭的肌病仓鼠心脏的心脏成纤维细胞重新表达,并抑制细胞重力和纤维状胶原代谢”循环 96・10。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Matsubara H,Inada M: "Molecular insights into angiotensin II type 1 and type 2 receptors : expression, signaling and physiological function and clinical application of its antagonists" Endocr J (Review). 45(2). 137-50 (1998)
Matsubara H、Inada M:“血管紧张素 II 1 型和 2 型受体的分子见解:其拮抗剂的表达、信号传导和生理功能及其临床应用”Endocr J(评论)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kijima K,Matsubara H,Murasawa S,Maruyama K,Mori Y,Inada M: "Gene transcription of angiotensin II type 2 receptor is repressed by growth factors and glucocorticoids in PC12 cells" Biochem Biophs Res Commun. 216. 359-366 (1995)
Kijima K、Matsubara H、Murasawa S、Maruyama K、Mori Y、Inada M:“PC12 细胞中血管紧张素 II 2 型受体的基因转录受到生长因子和糖皮质激素的抑制”Biochem Biophs Res Commun。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Matsubara H: "Pathophysiological roles of angiotensin II type 2 receptor in cardiovascular." Circ Res. 83.1. 1182-1191 (1998)
Matsubara H:“血管紧张素 II 2 型受体在心血管中的病理生理学作用。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Matsubara H 他11人: "Angiotensin Type 2 Receptor Are Re-expressed by Cardiac Fibroblasts..." Circulation. 96. 3954-3962 (1997)
Matsubara H 和其他 11 人:“血管紧张素 2 型受体由心脏成纤维细胞重新表达......”循环。 96. 3954-3962 (1997)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATSUBARA Hiroaki其他文献

MATSUBARA Hiroaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATSUBARA Hiroaki', 18)}}的其他基金

A molecular link between metabolic syndrome and energy metabolism in the heart
代谢综合征与心脏能量代谢之间的分子联系
  • 批准号:
    23659423
  • 财政年份:
    2011
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Identification of priming factors that determine cardiac lineage of cardiac stem cells
确定心脏干细胞心脏谱系的启动因子的鉴定
  • 批准号:
    20249046
  • 财政年份:
    2008
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Cardiac Repair of Severe Heart Failure by Human Heart- or Skeletal Muscle-Derived Multipotent Stem Cells
人类心脏或骨骼肌来源的多能干细胞对严重心力衰竭的心脏修复
  • 批准号:
    17209028
  • 财政年份:
    2005
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Angiogenic Cell Therapy by Bone Marrow-Derived Monocyte-lineage Stem Cells
骨髓来源的单核细胞谱系干细胞的血管生成细胞疗法
  • 批准号:
    15390254
  • 财政年份:
    2003
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic angiogenesis by transplantation of bone marrow stem cells
通过骨髓干细胞移植进行治疗性血管生成
  • 批准号:
    13470152
  • 财政年份:
    2001
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Angiotensin II Type 2 (AT2) Receptor Singnal and Cardiovascular Action
血管紧张素 II 2 型 (AT2) 受体信号和心血管作用
  • 批准号:
    11470166
  • 财政年份:
    1999
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular-mechanism for nephrogenic diabetes insipidus
肾性尿崩症的分子机制
  • 批准号:
    07671164
  • 财政年份:
    1995
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of thyroid hormone response element of atrial natriuretic factor
心房钠尿因子甲状腺激素反应元件的鉴定
  • 批准号:
    04833025
  • 财政年份:
    1992
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
  • 批准号:
    493141
  • 财政年份:
    2023
  • 资助金额:
    $ 8.45万
  • 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
  • 批准号:
    10734120
  • 财政年份:
    2023
  • 资助金额:
    $ 8.45万
  • 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
  • 批准号:
    445961
  • 财政年份:
    2021
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
  • 批准号:
    19K17401
  • 财政年份:
    2019
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
  • 批准号:
    411570
  • 财政年份:
    2019
  • 资助金额:
    $ 8.45万
  • 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
  • 批准号:
    391615
  • 财政年份:
    2018
  • 资助金额:
    $ 8.45万
  • 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
  • 批准号:
    26460229
  • 财政年份:
    2014
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
  • 批准号:
    25870715
  • 财政年份:
    2013
  • 资助金额:
    $ 8.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8531707
  • 财政年份:
    2012
  • 资助金额:
    $ 8.45万
  • 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
  • 批准号:
    8397394
  • 财政年份:
    2012
  • 资助金额:
    $ 8.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了